GASTROPARESIS TREATMENT MARKET ANALYSIS

Gastroparesis Treatment Market, By Drug Class (Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Others), By Disease Indication (Diabetes Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), By Type (Over-the-Counter Drugs and Prescription Drugs), By Route of Administration (Oral, Injectables, Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In December 2023, Vanda Pharmaceuticals Inc. announced that the FDA had accepted its New Drug Application (NDA) for tradipitant to treat gastroparesis symptoms. The FDA’s target decision date is September 18, 2024. If approved, tradipitant would be the first new drug for gastroparesis in over 40 years and the first to be reviewed by the FDA in more than 30 years.
In October 2023, Enterra Medical, Inc. announced that the Enterra II System had received MR Conditional approval from the FDA. This advanced treatment system, including the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, is designed to alleviate nausea and vomiting caused by gastroparesis. With MR Conditional status, patients with the Enterra II System can safely undergo MRI scans of the head or limbs under specific conditions.
In August 2022, Processa Pharmaceuticals, Inc. launched its Phase 2A clinical trial for PCS12852, enrolling the first patient with moderate to severe gastroparesis
In February 2022, Vanda Pharmaceuticals Inc. (Vanda) announced the results of its Phase III clinical trial, VP-VLY-686-3303, demonstrating the effectiveness and safety of tradipitant in treating symptoms of gastroparesis